Expiration Date: June 21, 2017
Media: Internet - based
Chemotherapy-induced nausea and vomiting (CINV) has far-reaching effects. CINV impairs quality of life, negatively impacts nutritional status, interferes with chemotherapy treatment, elevates the risk of nonadherence to chemotherapy, and increases the use of health care resources. Therapeutic advances in this field have resulted in a better understanding of CINV pathophysiology, and personalizing therapy for CINV according to patient risk factors and chemotherapy regimens. New antiemetic agents address some of the major unmet clinical needs in preventing and treating CINV, and it is critical for practitioners to understand novel mechanisms of action for these therapies and apply practice-changing evidence and guidelines to optimize care. For this activity, we are bringing together a panel of internationally recognized experts in the field to discuss how we can advance the care of these patients at risk for CINV.
CME Activity Table of Contents
- Risk Factors for Chemotherapy-Induced Nausea and Vomiting (CINV)
- Emetogenicity of Chemotherapeutic Agents
- Optimizing the Prevention and Management of CINV
- The Multidisciplinary Approach to Counseling Patients on CINV
- CINV Research: Moving Forward
- CINV Guidelines: Barriers to Adherence
- CINV Guidelines: Increasing Adherence
- CINV Guidelines: Incorporating Into Practice
- Managing CINV: Beyond Pharmacologic Therapy
- CINV: Patient Counseling Approaches
Instructions For This Activity & Receiving Credit
This educational activity is directed toward nurses and other health care professionals involved in the treatment of cancer patients, both at risk for and experiencing CINV.
Educational ObjectivesAt the conclusion of this activity, you should be better prepared to:
- Explain the classification of CINV and risk factors associated with its development
- Describe clinical trial evidence underlying the use of antiemetic strategies in the management of CINV
- Apply current clinical practice guidelines for the prevention and management of CINV to the management of real-world clinical scenarios in which patients with cancer are managed
Faculty, Staff, and Planners' DisclosuresProgram Chair
Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Disclosure: Consultant: Merck, Tesaro, Helsinn, Eisai; Other Support: Honoraria: Merck, Helsinn, Eisai.
Rebecca Clark-Snow, RN, BSN, OCN
Clinical Nurse Coordinator
The University of Kansas Cancer Center
Disclosure: No relevant financial relationships with commercial interests.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise